

Byetta - (250MCG/ML; Injectable, Subcutaneous)

Generic Name	EXENATIDE SYNTHETIC	Innovator	Astrazeneca
Dosage	250MCG/ML; Injectable, Subcutaneous	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.